Author: Estella, Ãngel; Garmendia, Jose LuÃs Garcia; de la Fuente, Carmen; Casas, Juan F. Machado; Yuste, Maria Eugenia; Villar, Rosario Amaya; Antonia Estecha, Mª; Mateos, Luis Yaguez; Bulnes, Maria Luisa Cantón; Loza, Ana; Ordoñez, Juan Miguel Mora; Ruiz, Laura Fernández; Fernández, Beatriz DÃez del Corral; Amezcua, Maria Rojas; Higueras, Maria Isabel Rodriguez; Torres, Isabel DÃaz; Núñez, MarÃa Recuerda; Beryanaki, Mehdi Zaheri; Espinar, Francisco Rivera; Zapata, Diego Fernando Matallana; Cano, Sara Guadalupe Moreno; Beltrán, Barbara Gimenez; Muñoz, Noelia; Sainz de Baranda Piñero, Andrés; Bueno, Pedro Bustelo; Barriga, Elvira Moreno; Toro, Juan Jesús Rios; Ruiz, Miriam Perez; González, Carmen Gómez; Flores, Ana Breval; Bermejo Gomez, Alberto de San Jose; Ãngeles Ruiz Cabello Jimenez, Mª; MarÃn, MarÃa Guerrero; Ordiales, Ane Ortega; Tejero-Aranguren, Julia; MejÃas, Candela Rodriguez; Gomez de Oña, Julia; la Hoz, Celia de; Fernández, Dolores Ocaña; Cuadros, Sonia Ibañez; Montero, Jose Garnacho
Title: Predictive factors of six-week mortality in critically ill patients with SARS COV 2: a multicenter prospective study Cord-id: nhmxf61i Document date: 2021_3_8
ID: nhmxf61i
Snippet: Objective: The objective of the study is to identify the risk factors associated with mortality at six weeks, especially by analyzing the role of antivirals and munomodulators. Design: Prospective descriptive multicenter cohort study. Setting: 26 Intensive care units (ICU) from Andalusian region in Spain. Patients or participants: Consecutive critically ill patients with confirmed SARS-CoV-2 infection were included from March 8 to May 30. Interventions: None. Variables: Variables analyzed were d
Document: Objective: The objective of the study is to identify the risk factors associated with mortality at six weeks, especially by analyzing the role of antivirals and munomodulators. Design: Prospective descriptive multicenter cohort study. Setting: 26 Intensive care units (ICU) from Andalusian region in Spain. Patients or participants: Consecutive critically ill patients with confirmed SARS-CoV-2 infection were included from March 8 to May 30. Interventions: None. Variables: Variables analyzed were demographic, severity scores and clinical condition. Support therapy, drug and mortality were analyzed. An univariate followed by multivariate Cox regression with propensity score analysis was applied. Results: 495 patients were enrolled, but 73 of them were excluded for incomplete data. Thus, 422 patients were included in the final analysis. Median age was 63 years and 305 (72,3%) were men. ICU mortality: 144/422 34%; 14 days mortality: 81/422 (19,2%); 28 days mortality: 121/422 (28,7%) ; 6-week Mortality 152/422 36.5%. By multivariable Cox proportional analysis, factors independently associated with 42-day mortality were age, APACHE II score, SOFA score at ICU admission >6, Lactate dehydrogenase at ICU admission > 470 U/L, Use of vasopressors, extrarenal depuration, %Lymphocytes 72 h post-ICU admission <6,5%, and thrombocytopenia whereas the use of lopinavir/ritonavir was a protective factor. Conclusion: Age, APACHE II, SOFA > value of 6 points, along with vasopressor requirements or renal replacement therapy have been identified as predictor factors of mortality at six weeks.
Search related documents:
Co phrase search for related documents- absolute frequency and acute respiratory: 1, 2
- absolute frequency and logistic regression model: 1
- acute infection and admission level: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21
- acute infection and admission score: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23
- acute infection and load reduction: 1, 2, 3, 4, 5, 6, 7, 8, 9
- acute infection and logistic regression model: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38
- acute infection and lombardy region: 1, 2, 3, 4
- acute infection and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33
- acute infection and lopinavir ritonavir treatment: 1, 2, 3, 4, 5
- acute infection and loss high number: 1
- acute infection and lymphocyte neutrophil: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43
- acute infection and lymphocyte neutrophil ratio: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31
- acute infection and lymphocyte ratio: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37
- acute infection and lymphocytes percentage: 1, 2, 3, 4, 5, 6, 7
- acute infection and lymphocytes ratio: 1, 2, 3, 4, 5
- acute infection and lymphopenia presence: 1
- acute infection and lymphopenia present: 1, 2, 3
- acute respiratory and admission level: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56
- acute respiratory and admission score: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72
Co phrase search for related documents, hyperlinks ordered by date